Not Primarily a Weight-Loss Drug: Semaglutide After a Second Heart Attack
A non-diabetic man with established coronary disease and obesity is offered semaglutide for cardiovascular risk reduction — a role the SELECT trial established independent of how much weight he actually loses.
Victor M., a 59-year-old retired postal worker, had his second heart attack eleven weeks ago, four years after his first, and arrived at this follow-up visit having already decided on his own that something bigger than another medication adjustment needed to change. He's not diabetic — has never had an A1c above 5.8% in the fifteen years his chart has been tracked — but he's carried a BMI in the low 30s since his forties, weight he describes with more resignation than urgency, the kind of thing he'd stopped actively fighting somewhere around his first MI. His route on the mail truck used to keep him walking six miles a day; a knee replacement two years ago cut that down to almost nothing, and he's noticed, without needing a chart to tell him, that the weight has crept up since.
His case sits close enough to a specific, recently reported trial population that the resemblance is worth naming directly: established cardiovascular disease, a BMI of 32, no diabetes, on background statin therapy — nearly the exact profile of the 17,604 patients enrolled in the SELECT trial, which found that semaglutide reduced the risk of cardiovascular death, nonfatal MI, or nonfatal stroke by 20% relative to placebo over a mean of just over three years of follow-up. Two prior MIs on maximal background therapy is precisely the kind of residual, unaddressed risk that trial was built to test against — not a patient whose statin and antiplatelet regimen had failed, but one whose risk clearly extended beyond what that regimen alone was ever going to close.
What makes today's conversation more than a straightforward prescription is how that benefit is actually described to him, since a drug this associated with weight loss in the public imagination risks being heard as one thing when the trial that justifies using it here was actually testing for something else entirely.
In follow-up, a trial population and a real patient
I'd start semaglutide here, and not primarily for the weight loss. SELECT randomized 17,604 patients with established cardiovascular disease and a BMI of 27 or higher, all without diabetes, to semaglutide or placebo, and found a 20% relative reduction in the composite of cardiovascular death, nonfatal MI, or nonfatal stroke — hazard ratio 0.80. He matches that population almost exactly: established disease, elevated BMI, no diabetes.
I agree with the recommendation, but I want to correct how it gets explained to him, because this matters for what he expects. SELECT's own subsequent analyses found the cardiovascular benefit was largely independent of how much weight a patient actually lost — some of the benefit showed up even in patients with modest weight loss. If we frame this to him purely as a weight-loss drug with a cardiovascular bonus, and he loses less weight than a friend on the same drug, he may wrongly conclude it isn't working for him.
Semaglutide should be discussed here as a disease-modifying cardiovascular drug that happens to also reduce weight, not the other way around — the trial's own data support describing it in that order, not the more familiar one.
That's a genuinely important correction and I'll adopt it directly in how I counsel him. It also bears on his GI side-effect tolerance: SELECT's own discontinuation rate for adverse events was meaningfully higher on semaglutide than placebo, so I'd start low and titrate slowly regardless of how quickly he wants to see the number on the scale move, since the cardiovascular benefit doesn't depend on getting there fast.
Agreed: start semaglutide, titrated slowly, explained to Victor explicitly as a cardiovascular risk-reduction therapy that also tends to reduce weight, not the reverse. Both physicians wanted him to understand that the trial supporting this decision measured heart attacks and strokes, not pounds, so his own success on the drug shouldn't be judged by the scale alone.
The endocrinologist's framing point was adopted without disagreement once raised; there was no unresolved tension left in this case by the end of the visit, only a shared plan for how it would be explained.